StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) from a sell rating to a hold rating in a report published on Friday.
Other analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th.
Abeona Therapeutics Trading Up 1.2 %
Hedge Funds Weigh In On Abeona Therapeutics
Large investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its holdings in Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after acquiring an additional 429,456 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth $1,732,000. abrdn plc increased its holdings in shares of Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Western Standard LLC lifted its stake in shares of Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More
- Five stocks we like better than Abeona Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- How to Effectively Use the MarketBeat Ratings Screener
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- 3 Small Caps With Big Return Potential
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.